BSX Boston Scientific Corporation Common Stock

NYSE · Health Care · SEC EDGAR पर देखें ↗
$51.46
मूल्य · अग 19, 2026
मौलिकता इस प्रकार है अग 3, 2026
52W रेंज
$42–$110
14% of range
विश्लेषक रेटिंग
BUY
38 analysts
मूल्य लक्ष्य
$63
+22% upside
P/E (TTM)
49.1
ROE
12.6%
शुद्ध लाभ मार्जिन
14.4%

Boston Scientific Corporation Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

और पढ़ें

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator (ICD) called the EMBLEM subcutaneous implantable defibrillator (S-ICD).

Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.

BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

History

Boston Scientific was formed on June 29, 1979, in Watertown, Massachusetts, as a holding company for the medical products company Medi-Tech, Inc., and to position the company for growth in interventional medicine. Medi-Tech was the brainchild of Itzhak Bentov, a Czech-born émigré to Israel and then to the United States, who worked at the Arthur D. Little think tank in Cambridge, Massachusetts, and ran a contract research company from his rented house in Belmont, Massachusetts, a venture he founded in 1965 with a business friend, Dan Singer.

In 1967 Bentov was asked by Boston Beth Israel Hospital radiologists to design a steerable, remotely controlled catheter; a series of engineering designs, polymer improvements and prototypes led to the release of a new steerable angiography catheter in 1969. That year John Abele joined the small company with an option to buy. A year later he exercised his option with Cooper Labs as a business partner, and the operation was moved – out of Bentov's lab in the basement of the rectory of a Catholic church in Belmont – to Watertown.

After a decade of steady growth, Abele met Pete Nicholas by chance in their neighborhood in Concord, Massachusetts. Their partnership hinged on Nicholas' goal to build business enterprises and Abele's predilection for the vision and potential in noninvasive surgical instrumentation; they gathered backers in the Boston banking community to buy out the Cooper Labs interest and form the new corporation.

Less than a year later Kimray Medical Associates (later Mansfield Scientific, Inc.) was acquired, adding vena cava filters and cardiac output computers to the product line. By 1982 a renovated mill building in Watertown was transformed into a manufacturing plant. Acquisitions continued, with Endo-Tech (Microvasive, Inc.: gastrointestinal and pulmonary) in 1981 and then Van-Tec (urology) in 1988, and an international presence was expanded. Mansfield Scientific, Microvasive, and Medi-Tech merged into Boston Scientific December 31, 1988.

Initial public offering (1992)

On May 19, 1992, Boston Scientific launched an initial public offering of 23.5 million shares, of which 18.8 million were offered in the U.S. and 4.7 million were offered outside the U.S. The initial offering amounted to 23% of Boston Scientific's outstanding stock.

Goldman, Sachs & Co. (lead) and PaineWebber Inc. were the underwriters and Abbott Laboratories held a 20% stake (23.5 million shares). The market capitalization was about $1.6 billion. The U.S. shares were listed on the New York Stock Exchange.

Post–IPO

From 1995 through 1997, Boston Scientific increased its technology R&D and product offerings following substantial acquisitions that included Cardiovascular Imaging Systems (intravascular ultrasound), SCIMED (cardiovascular), Vesica Medical (urology), Meadox (textile vascular prostheses), EP Technologies (cardiac ablation controllers), MinTec (abdominal aortic aneurysm grafts), Symbiosis Corporation (specialty medical product manufacture).

On November 3, 1998, Boston Scientific restated its financial results for 1997, as well as its quarterly results for the first three quarters of 1998, due to the occurrence of business irregularities in the operations of its Japanese subsidiary.

In 2001, Boston Scientific acquired Target Therapeutics (neurology) in a tax-free stock swap for about $1.1 billion, more than 10 times Target's total sales, in contrast to the usual multiple of 10 times earnings.

The Taxus Stent was approved in 2003 in Europe and other countries and, in the United States, by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.

In April 2004, the company announced that it had exercised an exclusive option to acquire Precision Vascular Systems, Inc., as part of a series of agreements between Boston Scientific and Precision Vascular in 2002, for an undisclosed sum. In June, Boston Scientific acquired Advanced Bionics Corporation for $740 million in cash, plus earn out payments. In December, Boston Scientific completed its acquisition of Advanced Stent Technologies, Inc., for $120 million payable in Boston Scientific stock, plus the possibility of future contingent payments. AST had been developing stent and stent delivery systems specifically designed to address the anatomical needs of coronary artery disease in bifurcated vessels.

In April 2005, BSC exercised an exclusive option to acquire TriVascular, Inc., for an undisclosed sum and renamed it as Boston Scientific Santa Rosa Corporation, or BSSR. TriVascular was founded in January 1998 to develop less-invasive medical devices and procedures for treating abdominal aortic aneurysms, but BSC discontinued its endovascular aortic repair (EVAR) program in 2006. BSC also announced it had exercised its option to acquire CryoVascular Systems, Inc., and its proprietary angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries. In June Boston Scientific announced that its wholly owned subsidiary, Nemo I Acquisition, Inc., had successfully acquired Salt Lake City-based Rubicon Medical Corporation, with Rubicon became a wholly owned subsidiary of Boston Scientific.

In March 2008, BSC sold BSSR to TV2 Holding Company of Santa Rosa. Terms of the sale include $30 million in cash paid at the closing to BSC and a warrant allowing BSC to purchase a minority interest in TV2.

Guidant merger

In January 2006, the company announced an offer for its longtime competitor, Guidant, for $72 per share or $25 billion. The offer, however, was rejected. On April 21, 2006, BSC acquired Guidant for $27.2 billion. Guidant was split between BSC and Abbott Laboratories. Four years later, in 2010, when moving its heart-rhythm business from its acquisition of Guidant, Boston Scientific eliminated 1300 jobs.

Post-merger

In December 2007, Boston Scientific announced it would sell its Fluid Management and Venous Access businesses for $425 million to Avista Capital Partners.

In April 2008, the company acquired CryoCor, Inc., for $1.35 per share, $17.6 million in total. Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.

In January 2009, Boston announced it would acquire Labcoat Limited, whose primary development was that of a development-stage drug-eluting stent – for an undisclosed sum.

2010–2020

In October 2010, the company was fined $600,000 by the US Department of Justice for paying a US Army doctor to use their devices and recommend them to others. In the same month Boston Scientific acquired Asthmatx, Inc., for $193.5 million, with payments of up to $250 million being paid on the achievement of specified revenue-based criteria through 2019.

In January 2011, Boston acquired Atritech, Inc., for $100 million, plus up to $275 million in additional potential payments. In the same month, Boston Scientific acquired Intelect Medical, Inc., for $78 million and the remaining 86% of Sadra Medical, Inc., not already owned for $193 million plus contingent payments. At the same time, the business divested its neurovascular business to Stryker Corporation for $1.5 billion.

In June 2012, Boston Scientific officially acquired Cameron Health for a total sum of $1.3 billion, paid out incrementally as various revenue milestones were achieved. In September, the company announced it would acquire BridgePoint Medical, Inc., developer of a catheter-based system to treat coronary chronic total occlusions. In October, the company acquired Rhythmia Medical, Inc., developer of mapping and navigation methods for use in cardiac catheter ablations and other electrophysiology procedures. A month later, the business acquired catheter-based renal denervation system developer, Vessix Vascular, Inc.

In November 2013, Boston announced it would acquire Bard EP, the electrophysiology business of C.R. Bard, Inc. for $275 million.

In May 2014, Boston acquired hysteroscopic intrauterine tissue removal specialist, IoGyn, Inc. In September, the business announced it would acquire the Interventional business of Bayer.

In March 2015, the company announced it would acquire Endo International Plc's American Medical Systems urology business for at least $1.6 billion, expanding the company's health and prostate treatments. In April, Boston announced its intention to acquire Xlumena, Inc. In October Boston announced it had invested further in percutaneous mitral valve replacement system developer, MValve Technologies, gaining a right to acquire the business in the future.

In July 2016, the business acquired the manufacturer of radiofrequency ablation systems, Cosman Medical, Inc. In September, Boston Scientific announced it had acquired EndoChoice Holdings, Inc., becoming part of the Boston Scientific Endoscopy business for $210 million. In November, the company acquired the gynecology and urology portfolio of Distal Access, LLC, a company that designs minimally invasive medical devices. In December 2016, the business acquired a 15% stake in Neovasc, Inc., for $75 million.

In 2016, Boston Scientific acquired EndoChoice, located in Alpharetta, Georgia.

In May 2017, the company acquired Symetis SA, a developer of minimally invasive transcatheter aortic valve implantation devices. In October, Boston acquired Apama Medical Inc. for up to $300 million.

In April 2018, Boston Scientific announced the triple closure of its acquisitions of women's health company, nVision Medical Corporation, NxThera and Securus Medical Group, Inc., for up to $50 million. In July, Boston Scientific announced it would acquire Cryterion Medical, Inc, Veniti, Inc., in August Augmenix, Inc., and Claret Medical, Inc. In November, Boston Scientific announced it would acquire UK medical device maker BTG plc for $4.2 billion. In late December, the company announced it would acquire Millipede, Inc for $325 million, after previously investing $90 million in the company.

In May 2019, the company announced it would acquire Vertiflex, Inc., with the aim of increasing its interventional pain therapy offerings. Vertiflex principally developed treatment for lumbar spinal stenosis.

2021–present

In January 2021, Boston announced it would acquire Minneapolis-based Preventice Solutions, Inc., and its portfolio of mobile cardiac health solutions for up to $1.2 billion. In March, the business announced it would acquire the surgical business part of Lumenis Ltd. for $1 billion from an affiliate of Baring Private Equity Asia, who, in 2019, had acquired Lumenis from XIO Group. In June, the company announced it would acquire the 73% of Farapulse, Inc., it did not already own, for $295 million. Farapulse was a University of Iowa startup. In September, the business announced it would acquire Devoro Medical, Inc., and its blood clot capturing technology. Boston Scientific had been a strategic investor in Devoro since 2019. In October, the company announced it would acquire Baylis Medical Company Inc. for $1.75 billion, expanding its electrophysiology and heart product portfolios (see Frank Baylis).

In June 2022, the Boston Scientific announced it would acquire M.I.Tech Co., Ltd., of South Korea, for around $230 million. The deal was cancelled in May 2023 citing regulatory hurdles. In August, Boston announced it would acquire Obsidio, Inc.

In June 2022, Boston Scientific announced that it would invest $62.5 million in a manufacturing and supply chain facility in Johns Creek, Georgia, a suburb of Atlanta.

In September 2023, Boston Scientific acquired Relievant Medsystems, Inc. for an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.

In January 2024, the company announced it would acquire Axonics, Inc. for $3.7 billion.

In January 2026, Boston Scientific announced it would acquire Penumbra in a ~$15 billion cash and stock deal. The deal was expected to close by yearend.

Corporate governance

Michael F. Mahoney is the current Boston Scientific chairman and chief executive officer.

Organizational culture

The journal US Black Engineer & Information Technology (USBE & IT), in its "2021 Top Supporters of HBCU Engineering," ranked BSC No. 6 among the "Top 20 Industry Supporters."

Financials

Litigation

Johnson & Johnson patent litigation

Beginning in 2003, Boston Scientific and Johnson & Johnson were involved in a series of litigations involving patents covering heart stent medical devices. Both parties claimed that the other had infringed upon their patents. The litigation was settled once Boston Scientific agreed to pay $716 million to Johnson & Johnson in September 2009 and an additional $1.73 billion in February 2010.

It was announced in November 2014 that Johnson & Johnson would have another chance for payback after a multibillion-dollar trial was set for November 20, 2014. A New York federal court judge would hear the case without a jury to decide whether Boston Scientific should be held liable for the contract breach.

Transvaginal mesh

Boston Scientific is one of several manufacturers of a medical device called transvaginal mesh, a type of surgical mesh used to treat pelvic organ prolapse. Experts concluded that the medical company had used cheap, counterfeit resin, which was both toxic and degraded when exposed to oxygen. When this was announced on 60 Minutes, Boston Scientific responded by saying the broadcast was "irresponsible and misleading," citing a 2017 Food and Drug Administration (FDA) report stating that although they found variability in the polypropylene resin, "these differences do not present new safety or effectiveness concerns." One woman, who sued in 2011, was awarded $100 million. Two operations had failed to remove all the parts of the mesh and she was still in pain. The company appealed the decision and had the amount reduced to $10M. In 2015, Boston Scientific announced it would pay $119 million to 2,970 lawsuit plaintiffs, who had been injured by the mesh. On March 23, 2021, the company agreed to pay $189 million to settle allegations that it had seriously misrepresented the risks related to the vaginal mesh. As of Jan. 27, 2021, around 54,000 lawsuits related to transvaginal meshes had been filed against Boston Scientific.

In April 2019, the FDA ordered Boston Scientific and Coloplast to remove all of their vaginal mesh products from the United States market. In 2020, Johnson & Johnson was required to pay $344 million for failing to disclose the serious product risks of its transvaginal mesh product.

NIR stent

In 2005, Boston Scientific paid $74 million to settle allegations that it had continued to sell NIR stents (flexible stents) after learning that many of them were defective. Twenty-six injuries and one death may have been caused by malfunctioning stents.

Defective defibrillators

In 2011, Guidant, a subsidiary of Boston Scientific, was criminally convicted of a failure to report defibrillator safety problems to the FDA. The company was forced to pay more than $296 million in criminal fines and had to submit to the supervision of the U.S. Probation Office for three years.

Even though Guidant knew the devices were defective, they continued to sell the defibrillators anyway. Guidant LLC had also advised its sales representatives to tell physicians that nothing was wrong with the defibrillators, and told the FDA that the proposed corrections were not being done to correct life-threatening device flaws, but were rather to improve process throughout. Not until three deaths had occurred and ten months had passed did the company reveal the defects in 2005. The directives for these wrongdoings had been implemented prior to Boston Scientific's acquisition of Guidant in 2006.

In 2013, BSC and three of its subsidiaries – Guidant LLC, Guidant Sales LLC, and Cardiac Pacemakers, Inc. – agreed to pay $30 million to settle allegations that, according to the Justice Department, between 2002 and 2005, Guidant knowingly sold defective heart devices to health care facilities that in turn implanted the devices into Medicare patients.

Bribery allegations

In 2009, Boston Scientific agreed to pay $22 million to settle allegations that its subsidiary Guidant LLC had used kickback schemes to boost sales for its pacemakers (cardiac rhythm management or CRM devices) and defibrillators (implantable cardioverter-defibrillators or ICD devices). Allegedly, Guidant paid doctors between $1,000 and $1,500 each to participate in one of its four post-studies known as RaCE ($1,500), RaCE II ($1,000), RaCE III ($1,000), and MERITS ($1,000).

Obsidio Embolic recall

In April 2024, the FDA announced a recall of Boston Scientific's device Obsidio Embolic, which is used to stop hemorrhaging and excessive bleeding. It has been found that when the device is paired with the aliquot technique, it can lead to bowel ischemia, which can mean longer hospitalization or death for patients.

Notable people

Donald Steven Baim, MD (1946–2009), served Chief Medical and Scientific Officer for Boston Scientific from 2006 until his death in 2009.

Ian Meredith, MD, PhD, AM (born 1956), was Global Chief Medical Officer and Executive Vice President from 2017 to 2023.

Ursula Burns (born 1958), who served as a Member of Boston Scientific's 13-seat Board of Directors since 2002, resigned after being named Chief Executive Officer of the Xerox Corporation, taking effect July 1, 2009, and becoming the first African-American female CEO of a Fortune 500 company.

Kristina M. Johnson (born 1957), PhD, who served as a Member of BSC's Board since May 2006, resigned in May 2009 after being confirmed by the U.S. Senate to serve as Under Secretary in the Department of Energy (see Under Secretary of Energy for Infrastructure & Under Secretary of Energy for Science and Innovation). Johnson was re-elected to BSC's board January 1, 2011, and served in that position until May 2017.

Yoshiaki Fujimori (born 1951), BSC Board Member since July 2016.

James Robert Tobin Jr. (born 1944), President & CEO of BSC from 1999 through 2009.

John Raymond Elliott "Ray" (born 1950), served as a Board Member from September 2007 to 2009, then, in July 2009, re-joined the Board and became President & CEO, a position he held until December 31, 2011. Before, he had served as Chairman of Zimmer Holdings, Inc., from August 6, 2001, to November 30, 2007, and President & CEO from March 20, 2001, to May 2007.

Headquarters and regional centers

World headquarters: Marlborough, Massachusetts

Europe headquarters: Voisins-le-Bretonneux, France

Asia Pacific headquarters: Boston Scientific Asia Pacific Pte Ltd., Singapore

U.S. Government Affairs office: Washington, D.C.

Latin America headquarters: Weston, Florida

स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗

Wikidata ↗

BSX स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा

मूल्य
$51.45
मार्केट कैप
—
P/E (TTM)
49.1
EPS (TTM)
$1.94
राजस्व (TTM)
$20.07B
लाभांश प्रतिफल
—
ROE
12.6%
D/E ऋण/इक्विटी
—
52W रेंज
$42 – $110

BSX स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें

10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान

राजस्व और शुद्ध आय $20.07B
10-point trend, +139.4%
2016-12-31 → 2025-12-31
EPS $1.94
10-point trend, +676.0%
2016-12-31 → 2025-12-31
फ्री कैश फ्लो $3.66B
8-point trend, +230.4%
2017-12-31 → 2025-12-31
मार्जिन 14.4%
8-point trend, -3.3%
2017-12-31 → 2025-12-31

मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?

मेट्रिक
5Y रुझान
BSX
सहकर्मी माध्यिका
P/E (TTM)
5-point trend, -20.2%
49.1
26.3

लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC

मेट्रिक
5Y रुझान
BSX
सहकर्मी माध्यिका
Gross Margin (सकल मार्जिन)
5-point trend, +6.1%
69.0%
63.1%
Operating Margin (परिचालन मार्जिन)
5-point trend, +2322.2%
18.0%
—
Net Profit Margin (शुद्ध लाभ मार्जिन)
5-point trend, +1836.1%
14.4%
15.6%
ROA
5-point trend, +2677.8%
7.0%
7.6%
ROE
5-point trend, +2471.7%
12.6%
15.0%
ROIC
5-point trend, +2459.3%
12.7%
—

वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती

मेट्रिक
5Y रुझान
BSX
सहकर्मी माध्यिका
Current Ratio (वर्तमान अनुपात)
5-point trend, -11.1%
1.6
1.7
Quick Ratio (त्वरित अनुपात)
5-point trend, -23.3%
0.4
—

विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR

मेट्रिक
5Y रुझान
BSX
सहकर्मी माध्यिका
Revenue YoY (राजस्व YoY)
5-point trend, +68.9%
19.9%
—
Revenue CAGR 3Y (राजस्व CAGR 3Y)
5-point trend, +68.9%
16.5%
—
Revenue CAGR 5Y (राजस्व CAGR 5Y)
5-point trend, +68.9%
15.2%
—
EPS YoY
5-point trend, +181.2%
55.2%
—
Net Income YoY (शुद्ध आय YoY)
5-point trend, +177.8%
56.7%
—

प्रति शेयर मेट्रिक्स EPS, प्रति शेयर बुक वैल्यू, प्रति शेयर नकदी प्रवाह, प्रति शेयर लाभांश

मेट्रिक
5Y रुझान
BSX
सहकर्मी माध्यिका
EPS (Diluted) (EPS (तनुभूत))
5-point trend, +181.2%
$1.94
—

पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर

मेट्रिक
5Y रुझान
BSX
सहकर्मी माध्यिका

BSX विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड

खरीदें 38 विश्लेषक
  • मजबूत खरीद 11 28.9%
  • खरीदें 19 50.0%
  • होल्ड 8 21.1%
  • बेचें 0 0.0%
  • मजबूत बिक्री 0 0.0%

12-महीने का मूल्य लक्ष्य

29 विश्लेषक · 2026-08-19
मध्यिका लक्ष्य $60.00 +16.6%
माध्य लक्ष्य $62.69 +21.8%

Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि

औसत आश्चर्य
0.03%
Period EPS Actual EPS अनुमान आश्चर्य
30 जून 2026 $0.86 $0.84 0.02%
31 मार्च 2026 $0.80 $0.79 0.01%
31 दिसमबर 2025 $0.80 $0.79 0.01%
30 सितमबर 2025 $0.75 $0.72 0.03%
30 जून 2025 $0.75 $0.73 0.02%
31 मार्च 2025 $0.75 $0.68 0.07%

सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी

टिकर मार्केट कैप P/E राजस्व YoY शुद्ध मार्जिन ROE सकल मार्जिन
BSX — 49.1 19.9% 14.4% 12.6% 69.0%
ABT $250.18B 33.7 5.7% 14.7% 13.1% —
ISRG $201.11B 72.0 20.5% 28.4% 16.7% 66.0%
SYK $134.44B 41.8 11.2% 12.9% 15.1% 64.0%
EW $49.50B 46.6 11.6% 17.7% 10.6% 78.0%
BDX — 25.3 8.2% 7.7% 6.5% —
IDXX $53.93B 51.7 10.4% 24.6% 69.2% 61.8%
DXCM $25.54B 31.8 15.6% 17.9% 31.4% 60.1%
GEHC — 18.0 4.8% 10.1% 22.1% 40.0%
RMD $28.11B 18.7 9.8% 26.9% 23.6% 61.1%
ZBH $28.66B 25.3 7.2% 8.6% 5.6% —

पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह

आय विवरण 16
BSX के लिए वार्षिक आय विवरण डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +169.0% $20.07B $16.75B $14.24B $12.68B $11.89B $9.91B $10.73B $9.82B $9.05B $8.39B $7.48B $7.46B
Cost of Revenue 12-point trend, +181.5% $6.22B $5.26B $4.34B $3.96B $3.71B $3.46B $3.12B $2.81B $2.59B $2.42B $2.17B $2.21B
Gross Profit 12-point trend, +168.0% $13.85B $11.49B $9.90B $8.73B $8.18B $6.45B $7.62B $7.01B $6.46B $5.96B $5.30B $5.17B
SG&A Expense 12-point trend, +137.3% $6.89B $5.98B $5.19B $4.52B $4.36B $3.79B $3.94B $3.57B $3.29B $3.10B $2.87B $2.90B
Operating Expenses 12-point trend, +87.2% $10.24B $8.89B $7.55B $7.08B $6.98B $6.53B $6.10B $5.50B $5.17B $5.51B $5.59B $5.47B
Operating Income 12-point trend, +1300.3% $3.61B $2.60B $2.34B $1.65B $1.20B $-80M $1.52B $1.51B $1.28B $447M $-283M $-301M
Interest Expense 12-point trend, +61.6% $349M $305M $265M $470M $341M $361M $473M $241M $229M $233M $284M $216M
Other Non-op 12-point trend, -2950.0% $-228M $-321M $-358M $-508M $218M $362M $-358M $156M $-124M $-37M $-83M $8M
Pretax Income 12-point trend, +765.0% $3.38B $2.28B $1.99B $1.14B $1.08B $-79M $687M $1.42B $933M $177M $-650M $-509M
Income Tax 12-point trend, +226.4% $493M $436M $393M $443M $36M $2M $-4.01B $-249M $828M $-170M $-411M $-390M
Net Income 12-point trend, +2530.3% $2.89B $1.85B $1.59B $698M $1.04B $-82M $4.70B $1.67B $104M $347M $-239M $-119M
EPS (Basic) 12-point trend, +2277.8% $1.96 $1.26 $1.08 $0.45 $0.69 $-0.08 $3.38 $1.21 $0.08 $0.26 $-0.18 $-0.09
EPS (Diluted) 12-point trend, +2255.6% $1.94 $1.25 $1.07 $0.45 $0.69 $-0.08 $3.33 $1.19 $0.08 $0.25 $-0.18 $-0.09
Shares (Basic) 12-point trend, +11.8% 1,480,400,000 1,471,500,000 1,453,000,000 1,430,500,000 1,422,300,000 1,416,700,000 1,391,500,000 1,381,000,000 1,370,100,000 1,357,600,000 1,341,200,000 1,324,300,000
Shares (Diluted) 12-point trend, +12.9% 1,494,500,000 1,485,900,000 1,463,500,000 1,439,700,000 1,433,800,000 1,416,700,000 1,410,600,000 1,401,400,000 1,392,700,000 1,377,200,000 1,341,200,000 1,324,300,000
EBITDA 10-point trend, +1074.8% $4.98B $3.87B · $2.79B $2.29B $1.04B $2.53B $2.40B $2.13B · $442M $424M
बैलेंस शीट 27
BSX के लिए वार्षिक बैलेंस शीट डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +234.8% $1.97B $414M $865M $928M $1.93B $1.73B $217M $146M $188M $196M $319M $587M
Inventory 12-point trend, +211.1% $2.94B $2.81B $2.48B $1.87B $1.61B $1.35B $1.58B $1.17B $1.08B $955M $1.02B $946M
Prepaid Expense 12-point trend, +49.0% $660M $831M $621M $731M $799M $751M $880M $921M $942M $541M $365M $443M
Other Current Assets 9-point trend, +227.2% · $831M $621M $731M $799M $751M $880M $921M · $240M $254M ·
Current Assets 12-point trend, +143.9% $8.79B $6.92B $6.51B $5.76B $6.32B $6.69B $4.70B $4.00B $3.82B $3.24B $3.47B $3.61B
PP&E (Net) 12-point trend, +167.8% $4.04B $3.29B $2.86B $2.45B $2.25B $2.08B $2.08B $1.78B $1.70B $1.63B $1.49B $1.51B
PP&E (Gross) 12-point trend, +98.8% $7.64B $6.83B $6.34B $5.73B $5.53B $5.31B $5.17B $4.74B $4.62B $4.37B $4.06B $3.85B
Accum. Depreciation 12-point trend, +54.3% $3.61B $3.53B $3.48B $3.28B $3.27B $3.22B $3.09B $2.96B $2.93B $2.73B $2.57B $2.34B
Goodwill 12-point trend, +210.0% $18.28B $17.09B $14.39B $12.92B $11.99B $9.95B $10.18B $7.91B $7.00B $6.68B $6.47B $5.90B
Intangibles 12-point trend, +25.2% $7.02B $6.68B $6.00B $5.90B $6.12B $5.92B $7.89B $6.37B $5.84B $5.88B $6.19B $5.61B
Other Non-current Assets 12-point trend, +191.2% $1.19B $1.75B $1.53B $1.50B $1.41B $1.92B $1.53B $845M $688M $666M $505M $407M
Total Assets 12-point trend, +156.5% $43.67B $39.40B $35.14B $32.47B $32.23B $30.78B $30.57B $21.00B $19.04B $18.10B $18.13B $17.02B
Accounts Payable 12-point trend, +336.6% $1.14B $960M $942M $862M $794M $513M $542M $349M $530M $447M $209M $262M
Accrued Liabilities 12-point trend, +64.2% $3.20B $2.77B $2.65B $2.16B $2.44B $2.20B $2.11B $2.25B $2.46B $2.31B $1.97B $1.95B
Current Liabilities 12-point trend, +91.1% $5.44B $6.40B $4.93B $3.80B $4.27B $3.68B $4.87B $5.26B $5.65B $3.59B $2.43B $2.85B
Capital Leases 8-point trend, +446000000.00 $446M $401M $390M $347M $389M $401M $276M $0 · · · ·
Deferred Tax 12-point trend, -81.9% $220M $155M $134M $144M $310M $330M $595M $328M $191M $18M $735M $1.21B
Other Non-current Liabilities 12-point trend, -9.8% $2.40B $1.87B $1.97B $2.04B $2.22B $2.31B $2.63B $1.88B $2.37B $2.34B $2.97B $2.67B
Long-term Debt 4-point trend, -9.2% · · · · · · · · $3.81B $5.42B $5.65B $4.20B
Total Debt 2-point trend, -100.0% · · · · · · · · · · $0 $400M
Common Stock 12-point trend, +6.2% $17M $17M $17M $17M $17M $17M $16M $16M $16M $16M $16M $16M
Retained Earnings 12-point trend, +164.1% $5.57B $2.67B $819M $-750M $-1.39B $-2.38B $-2.25B $-6.95B $-8.39B $-8.58B $-8.93B $-8.69B
Treasury Stock 12-point trend, +31.1% $2.25B $2.25B $2.25B $2.25B $2.25B $2.25B $1.72B $1.72B $1.72B $1.72B $1.72B $1.72B
AOCI 12-point trend, -523.6% $-610M $275M $49M $269M $263M $207M $270M $33M $-59M $1M $88M $144M
Stockholders' Equity 12-point trend, +275.3% $24.23B $21.77B $19.28B $17.57B $16.62B $15.33B $13.88B $8.73B $7.01B $6.73B $6.32B $6.46B
Liabilities + Equity 12-point trend, +156.5% $43.67B $39.40B $35.14B $32.47B $32.23B $30.78B $30.57B $21.00B $19.04B $18.10B $18.13B $17.02B
Shares Outstanding 6-point trend, +5.1% · · · · · · 1,394,922,641 1,384,581,760 1,373,496,628 1,362,104,547 1,346,647,516 1,327,451,966
नकदी प्रवाह 19
BSX के लिए वार्षिक नकदी प्रवाह डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
D&A 12-point trend, +88.7% $1.37B $1.27B $1.20B $1.14B $1.09B $1.12B $1.01B $894M $844M $815M $769M $725M
Stock-based Comp 12-point trend, +190.3% $299M $266M $233M $220M $194M $170M $157M $140M $127M $116M $107M $103M
Deferred Tax 12-point trend, +97.6% $-12M $-90M $73M $-7M $-142M $-85M $-4.29B $-162M $244M $-343M $-605M $-494M
Amort. of Intangibles 12-point trend, +104.8% $897M $856M $828M $803M $741M $789M $699M $599M $565M $545M $495M $438M
Restructuring 12-point trend, +46.4% $101M $16M $69M $24M $40M $52M $38M $36M $37M $28M $26M $69M
Other Non-cash 10-point trend, -101.2% $-13M $144M · $-521M $-316M $382M $256M $-2.23B $107M · $568M $1.05B
Operating Cash Flow 12-point trend, +257.3% $4.53B $3.44B $2.50B $1.53B $1.87B $1.51B $1.84B $310M $1.43B $1.18B $691M $1.27B
CapEx 12-point trend, +238.2% $876M $790M $711M $588M $554M $376M $461M $316M $319M $376M $247M $259M
Investing Cash Flow 12-point trend, -254.4% $-2.64B $-5.69B $-2.57B $-2.01B $-1.60B $-411M $-5.04B $-1.92B $-1.01B $-887M $-2.19B $-745M
Net Debt Issued 5-point trend, -3560000000.00 · · · · · · $-3.56B $-602M $-1.00B · $-1.15B $0
Stock Issued 9-point trend, -100.0% · · · $0 $0 $975M $0 $0 $85M $111M $114M $60M
Stock Repurchased 8-point trend, -100.0% · · · $0 $0 $535M $0 $0 · $0 $0 $125M
Net Stock Activity 8-point trend, +100.0% · · · $0 $0 $440M $123M $101M $85M · $114M $-65M
Dividends Paid 7-point trend, +0.00 · $0 $28M $55M $55M $28M $0 $0 · · · ·
Financing Cash Flow 12-point trend, -163.3% $-395M $1.81B $5M $-548M $-95M $293M $2.97B $1.43B $110M $-206M $1.28B $-150M
Net Change in Cash 11-point trend, +316.5% $1.54B $-450M $-70M $-1.04B $173M $1.39B $-222M $-188M · $-123M $-268M $370M
Taxes Paid $561M · · · · · · · · · · ·
Free Cash Flow 10-point trend, +262.2% $3.66B $2.65B · $938M $1.32B $1.13B $1.38B $-6M $1.11B · $353M $1.01B
Levered FCF 10-point trend, +250.2% $3.36B $2.40B · $650M $986M $762M $-1.86B $-289M $1.08B · $249M $960M
लाभप्रदता 8
BSX के लिए वार्षिक लाभप्रदता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Gross Margin 10-point trend, -0.4% 69.0% 68.6% · 68.8% 68.8% 65.0% 71.0% 71.4% 71.3% · 65.7% 69.3%
Operating Margin 10-point trend, +546.7% 18.0% 15.5% · 13.0% 10.1% -0.81% 14.1% 15.3% 14.2% · -4.0% -4.0%
Net Margin 10-point trend, +1006.3% 14.4% 11.0% · 5.5% 8.8% -0.83% 43.8% 17.0% 1.1% · -3.0% -1.6%
Pretax Margin 10-point trend, +347.2% 16.9% 13.6% · 9.0% 9.0% -0.80% 6.4% 14.5% 10.3% · -8.1% -6.8%
EBITDA Margin 10-point trend, +336.8% 24.8% 23.1% · 22.0% 19.3% 10.5% 23.6% 24.4% 23.5% · 5.5% 5.7%
ROA 10-point trend, +1080.3% 7.0% 5.0% · 2.2% 3.3% -0.27% 18.2% 8.3% 0.56% · -1.4% -0.71%
ROE 10-point trend, +786.9% 12.6% 8.7% · 4.0% 6.3% -0.53% 41.6% 21.2% 1.5% · -3.7% -1.8%
ROIC 10-point trend, +1336.9% 12.7% 9.7% · 5.7% 7.0% -0.54% 74.8% 20.3% 2.1% · -1.9% -1.0%
तरलता और शोधन क्षमता 4
BSX के लिए वार्षिक तरलता और शोधन क्षमता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Current Ratio 10-point trend, +27.6% 1.6 1.1 · 1.5 1.5 1.8 1.0 0.8 0.7 · 1.4 1.3
Quick Ratio 10-point trend, +75.1% 0.4 0.1 · 0.2 0.5 0.5 0.0 0.0 0.0 · 0.1 0.2
Debt / Equity 2-point trend, -100.0% · · · · · · · · · · 0.0 0.1
Interest Coverage 10-point trend, +842.9% 10.4 8.5 · 3.5 3.5 -0.2 3.2 6.2 5.6 · -1.2 -1.4
दक्षता 2
BSX के लिए वार्षिक दक्षता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Asset Turnover 10-point trend, +8.9% 0.5 0.4 · 0.4 0.4 0.3 0.4 0.5 0.5 · 0.5 0.4
Inventory Turnover 10-point trend, -9.8% 2.2 2.0 · 2.3 2.5 2.4 2.3 2.5 2.6 · 2.2 2.4
प्रति शेयर 5
BSX के लिए वार्षिक प्रति शेयर डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Book Value / Share 5-point trend, +104.5% · · · · · · $9.95 $6.30 $5.11 · $4.69 $4.86
Revenue / Share 10-point trend, +138.4% $13.43 $11.27 · $8.81 $8.29 $7.00 $7.61 $7.01 $6.50 · $6.02 $5.63
Cash Flow / Share 10-point trend, +216.6% $3.03 $2.31 · $1.06 $1.30 $1.06 $1.30 $0.22 $1.02 · $0.45 $0.96
Cash / Share 5-point trend, -64.8% · · · · · · $0.16 $0.11 $0.14 · $0.24 $0.44
EPS (TTM) 12-point trend, +2255.6% $1.94 $1.25 $1.07 $0.45 $0.69 $-0.08 $3.33 $1.19 $0.08 $0.25 $-0.18 $-0.09
विकास दरें 7
BSX के लिए वार्षिक विकास दरें डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -0.3% 19.9% 17.6% 12.3% 6.7% 19.9% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +28.9% 16.5% 12.1% 12.8% · · · · · · · · ·
Revenue CAGR 5Y 15.2% · · · · · · · · · · ·
EPS YoY 4-point trend, +258.7% 55.2% 16.8% 137.8% -34.8% · · · · · · · ·
EPS CAGR 3Y 2-point trend, +186.5% 62.7% 21.9% · · · · · · · · · ·
Net Income YoY 4-point trend, +272.0% 56.7% 16.0% 128.1% -33.0% · · · · · · · ·
Net Income CAGR 3Y 2-point trend, +188.1% 60.6% 21.0% · · · · · · · · · ·
मूल्यांकन (TTM) 16
BSX के लिए वार्षिक मूल्यांकन (TTM) डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +169.0% $20.07B $16.75B $14.24B $12.68B $11.89B $9.91B $10.73B $9.82B $9.05B $8.39B $7.48B $7.46B
Net Income TTM 12-point trend, +2530.3% $2.89B $1.85B $1.59B $698M $1.04B $-82M $4.70B $1.67B $104M $347M $-239M $-119M
Market Cap 5-point trend, +258.6% · · · · · · $63.08B $48.93B $34.05B · $24.83B $17.59B
Enterprise Value 2-point trend, +40.9% · · · · · · · · · · $24.51B $17.40B
P/E 12-point trend, +133.4% 49.1 71.5 54.0 102.8 61.6 -449.4 13.6 29.7 309.9 86.5 -102.4 -147.2
P/S 5-point trend, +149.3% · · · · · · 5.9 5.0 3.8 · 3.3 2.4
P/B 5-point trend, +66.9% · · · · · · 4.5 5.6 4.9 · 3.9 2.7
P / Cash Flow 5-point trend, +147.9% · · · · · · 34.4 157.8 23.9 · 41.4 13.9
P / FCF 5-point trend, +163.4% · · · · · · 45.9 -8155.2 30.8 · 70.3 17.4
EV / EBITDA 2-point trend, +35.1% · · · · · · · · · · 55.5 41.0
EV / FCF 2-point trend, +303.0% · · · · · · · · · · 69.4 17.2
EV / Revenue 2-point trend, +40.6% · · · · · · · · · · 3.3 2.3
Dividend Yield Flat — no change across 2 periods · · · · · · 0.00% 0.00% · · · ·
Earnings Yield 12-point trend, +398.5% 2.0% 1.4% 1.8% 0.97% 1.6% -0.22% 7.4% 3.4% 0.32% 1.2% -0.98% -0.68%
Payout Ratio 4-point trend, +100.0% · 0.00% · 7.9% 5.3% -34.2% · · · · · ·
Annual Payout 7-point trend, +0.00 · $0 $28M $55M $55M $28M $0 $0 · · · ·

वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष

आय विवरण
2025-12-312024-12-312023-12-312022-12-312021-12-31
राजस्व $20.07B$16.75B$14.24B$12.68B$11.89B
सकल मार्जिन % 69.0%68.6%—68.8%68.8%
परिचालन मार्जिन % 18.0%15.5%—13.0%10.1%
शुद्ध आय $2.89B$1.85B$1.59B$698M$1.04B
तनुकरणित EPS $1.94$1.25$1.07$0.45$0.69
बैलेंस शीट
2025-12-312024-12-312023-12-312022-12-312021-12-31
वर्तमान अनुपात 1.61.1—1.51.5
त्वरित अनुपात 0.40.1—0.20.5
नकदी प्रवाह
2025-12-312024-12-312023-12-312022-12-312021-12-31
फ्री कैश फ्लो $3.66B$2.65B—$938M$1.32B

ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां

मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ

📊

उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।

आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।

संस्थागत मालिक (13F) 1695 फाइलर्स · $37.7B कुल · तिथि अनुसार 30 जून 2026

संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।

संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
नई स्थितियाँ बाहर निकली पोजीशन बढ़ाया घटा हुआ शुद्ध शेयर परिवर्तन
171 (-64 पिछली तिमाही की तुलना में) 310 (+34 पिछली तिमाही की तुलना में) 593 (-92 पिछली तिमाही की तुलना में) 600 (-28 पिछली तिमाही की तुलना में) +164.8M

Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।

संस्था मूल्य शेयर % ट्रैक किए गए 13F का प्रकार
VANGUARD CAPITAL MANAGEMENT LLC $4143696762 97087553 10.98% शेयर
STATE STREET CORP $2992345845 70111196 7.93% शेयर
PRIMECAP MANAGEMENT CO/CA/ $2156232608 50520914 5.71% शेयर
VANGUARD PORTFOLIO MANAGEMENT LLC $1271556448 29792794 3.37% शेयर
FMR LLC $1239549312 29042861 3.28% शेयर
GEODE CAPITAL MANAGEMENT, LLC $1212072881 28557132 3.21% शेयर
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $994184207 23293913 2.63% शेयर
NORGES BANK $903536838 21170029 2.39% शेयर
TWO SIGMA INVESTMENTS, LP $826243102 19359023 2.19% शेयर
Capital World Investors $717600310 16812257 1.90% शेयर
JANE STREET GROUP, LLC $686580356 16086700 1.82% कॉल ऑप्शन
WELLINGTON MANAGEMENT GROUP LLP $633296809 14838257 1.68% शेयर
Capital Research Global Investors $605255716 14180571 1.60% शेयर
TWO SIGMA ADVISERS, LP $600558161 6298460 1.59% शेयर
FARALLON CAPITAL MANAGEMENT, L.L.C. $449044133 10521184 1.19% शेयर
CANADA PENSION PLAN INVESTMENT BOARD $395319403 9262404 1.05% शेयर
Qube Research & Technologies Ltd $381720146 8943771 1.01% शेयर
VANGUARD FIDUCIARY TRUST CO $356182867 8345428 0.94% शेयर
BNP PARIBAS FINANCIAL MARKETS $325241617 7620469 0.86% शेयर
MORGAN STANLEY $278890927 6534464 0.74% शेयर
D. E. Shaw & Co., Inc. $254250351 5957131 0.67% शेयर
MAVERICK CAPITAL LTD $253414762 5937553 0.67% शेयर
Ensign Peak Advisors, Inc $251016744 5881367 0.66% शेयर
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $243577742 3881717 0.65% शेयर
UBS Group AG $240594117 5637163 0.64% शेयर
JANE STREET GROUP, LLC $238521448 5588600 0.63% पुट ऑप्शन
BlackRock, Inc. $234043121 5483672 0.62% शेयर
LAZARD ASSET MANAGEMENT LLC $227443076 5329032 0.60% शेयर
Clearbridge Investments, LLC $218981454 5130774 0.58% शेयर
JARISLOWSKY, FRASER Ltd $214082478 2192794 0.57% शेयर
BANK OF AMERICA CORP /DE/ $211692928 4960003 0.56% शेयर
MILLENNIUM MANAGEMENT LLC $210735360 5437567 0.56% शेयर
DIMENSIONAL FUND ADVISORS LP $208893933 4894422 0.55% शेयर
1832 Asset Management L.P. $194487468 4556876 0.52% शेयर
Holocene Advisors, LP $180429700 4227500 0.48% कॉल ऑप्शन
Swiss National Bank $178906024 4191800 0.47% शेयर
JANE STREET GROUP, LLC $178652846 4185868 0.47% शेयर
Assenagon Asset Management S.A. $178127498 4173559 0.47% शेयर
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ $170906014 4042830 0.45% शेयर
National Pension Service $168995643 3959598 0.45% शेयर
Legal & General Group Plc $160927972 3770571 0.43% शेयर
Mitsubishi UFJ Asset Management Co., Ltd. $154393705 3617472 0.41% शेयर
Ninety One UK Ltd $149464716 3501985 0.40% शेयर
Sumitomo Mitsui Trust Group, Inc. $146301705 3427875 0.39% शेयर
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $144322114 2299954 0.38% शेयर
Employees Provident Fund Board $143349316 3358700 0.38% शेयर
Vanguard Global Advisers, LLC $142456877 3337790 0.38% शेयर
VOLORIDGE INVESTMENT MANAGEMENT, LLC $139790914 3275326 0.37% शेयर
SUSQUEHANNA INTERNATIONAL GROUP, LLP $135035252 3163900 0.36% कॉल ऑप्शन
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $134976349 3162285 0.36% शेयर
Caisse de depot et placement du Quebec $133178416 3120394 0.35% शेयर
Alecta Tjanstepension Omsesidigt $133002390 3117000 0.35% शेयर
Mirova US LLC $132371081 3101478 0.35% शेयर
BARCLAYS PLC $131524822 3081650 0.35% शेयर
VANGUARD ASSET MANAGEMENT, Ltd $122627792 2873191 0.32% शेयर
Public Sector Pension Investment Board $119712961 2804896 0.32% शेयर
MANUFACTURERS LIFE INSURANCE COMPANY, THE $115346242 2702583 0.31% शेयर
RHUMBLINE ADVISERS $112753784 2641843 0.30% शेयर
Rathbones Group PLC $108402974 2539901 0.29% शेयर
RENAISSANCE TECHNOLOGIES LLC $102944373 2412005 0.27% शेयर
Temasek Holdings (Private) Ltd $102407502 2399426 0.27% शेयर
Pictet Asset Management Holding SA $102158094 2393080 0.27% शेयर
Unisphere Establishment $101911304 2387800 0.27% शेयर
MILFORD FUNDS LTD $92593577 2169484 0.25% शेयर
ALLIANCEBERNSTEIN L.P. $91340092 1455619 0.24% शेयर
HSBC HOLDINGS PLC $90846130 2128541 0.24% शेयर
GOLDMAN SACHS GROUP INC $89773112 2103400 0.24% कॉल ऑप्शन
NOMURA HOLDINGS INC $88556732 2074900 0.23% कॉल ऑप्शन
Cubist Systematic Strategies, LLC $88171996 903124 0.23% शेयर
NEUBERGER BERMAN GROUP LLC $87691368 2054624 0.23% शेयर
California Public Employees Retirement System $87402153 2047848 0.23% शेयर
Phoenix Financial Ltd. $82560747 1934413 0.22% शेयर
Nuveen Asset Management, LLC $76820023 860054 0.20% शेयर
NEW YORK STATE COMMON RETIREMENT FUND $73919754 1731953 0.20% शेयर
SUSQUEHANNA INTERNATIONAL GROUP, LLP $73776648 1728600 0.20% पुट ऑप्शन
FIRST MANHATTAN CO. LLC. $72442215 1697334 0.19% शेयर
ADAGE CAPITAL PARTNERS GP, L.L.C. $71276539 1670022 0.19% शेयर
Banque Transatlantique SA $71260298 914874 0.19% शेयर
PRINCIPAL FINANCIAL GROUP INC $70441674 1650461 0.19% शेयर
ROYAL BANK OF CANADA $70272000 1646479 0.19% शेयर
Squarepoint Ops LLC $69351970 1624929 0.18% शेयर
D. E. Shaw & Co., Inc. $68616636 1607700 0.18% पुट ऑप्शन
GROUPAMA ASSET MANAGMENT $68098768 1571750 0.18% शेयर
Lansforsakringar Fondforvaltning AB (publ) $67481689 1581108 0.18% शेयर
Walleye Capital LLC $67356381 1578172 0.18% शेयर
Squarepoint Ops LLC $66922240 1568000 0.18% कॉल ऑप्शन
VANGUARD GROUP INC $66616468 698652 0.18% शेयर
GOLDMAN SACHS GROUP INC $65853458 1542958 0.17% शेयर
CAPITAL FUND MANAGEMENT S.A. $63426577 1486096 0.17% शेयर
ORBIMED ADVISORS LLC $63302976 1483200 0.17% शेयर
TUDOR INVESTMENT CORP ET AL $63065547 1477637 0.17% शेयर
CAXTON ASSOCIATES LP $62622699 701105 0.17% शेयर
ENVESTNET ASSET MANAGEMENT INC $62259456 1458786 0.16% शेयर
AVIVA PLC $61094158 1431447 0.16% शेयर
Navera Investment Management Ltd. $60925063 1427592 0.16% शेयर
Connor, Clark & Lunn Investment Management Ltd. $60808373 1424751 0.16% शेयर
JONES FINANCIAL COMPANIES LLLP $56948391 1287551 0.15% शेयर
MENORA MIVTACHIM HOLDINGS LTD. $56913780 1333500 0.15% शेयर
Schonfeld Strategic Advisors LLC $56634266 1326951 0.15% शेयर
DEERFIELD MANAGEMENT COMPANY, L.P. $56124200 1315000 0.15% शेयर

कंपनी के अंदरूनी सूत्र 90 इनसाइडर्स · 30 अधिकारी · 18 निदेशक

अंदरूनी भूमिका अंतिम गतिविधि शेयरों का स्वामित्व खरीद 12m बिक्री 12m नेट 12m
William Kucheman Chief Executive Officer 31 जुलाई 2012 P 112525 0 0 $0
James R Tobin President & CEO 24 फ़रवरी 2009 A 550000 0 0 $0
Jeffrey D Capello EVP & Chief Financial Officer 27 नवमबर 2013 S 447 0 0 $0
Paul A Laviolette COO 1 जुलाई 2008 M 63072 0 0 $0
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology 31 जुलाई 2026 I 64198 0 7 $-15168204
Karen Prange SVP&Pres, Uro & Pelvic Health 8 मार्च 2016 S 38395 0 0 $0
Jean Fitterer Lance SVP, Asst GC, Bus & Regions 16 फ़रवरी 2015 M 117174 0 0 $0
John Michael Onuscheck SVP & President, Europe 1 जनवरी 2015 M 116025 0 0 $0
Kenneth Pucel EVP, Glob Ops, Qual & Tech 28 फ़रवरी 2014 M 128517 0 0 $0
Otha T. Spriggs III SVP, Human Resources 7 सितमबर 2012 M 12738 0 0 $0
Lawrence R Neumann SVP, Special Projects 10 मई 2012 M 77879 0 0 $0
Brian R Burns EVP - Global Quality & Reg Aff 28 फ़रवरी 2012 M 79418 0 0 $0
John B. Pedersen Pres, Uro & Women's Health 16 फ़रवरी 2012 M 3233 0 0 $0
Stephen F Moreci SVP, Global Sales Operations 1 जुलाई 2011 M 37362 0 0 $0
Sam R Leno EVP & Chief Operations Officer 6 जून 2011 M 432240 0 0 $0
Fred Colen EVP & Chief Technology Officer 10 मई 2010 M 72497 0 0 $0
James Gilbert EVP, Strategy & Business Dev 26 फ़रवरी 2010 A 67613 0 0 $0
David W Mcfaul SVP, International 12 फ़रवरी 2010 M 41426 0 0 $0
Donovan Paul SVP, Corporate Communications 12 फ़रवरी 2010 M 33103 0 0 $0
William F Mcconnell JR SVP, Administration CRM 24 जुलाई 2009 M 55204 0 0 $0
Donald S Baim EVP, Chief Med. & Sci. Officer 10 जुलाई 2009 M 51756 0 0 $0
Lucia Luce Quinn Exec. Vice President-HR 1 जुलाई 2009 M 49809 0 0 $0
Paul W Sandman EVP and General Counsel 29 फ़रवरी 2008 M 66846 0 0 $0
Jeffrey H Goodman SVP, International 1 जुलाई 2007 M 10460 0 0 $0
Lawrence C Best EVP 1 जुलाई 2007 F 242189 0 0 $0
Mark C Bartell SVP Global Sales/Mkt CRM 25 मई 2007 M 1812 0 0 $0
Mary E Russell SVP and CMO 3 जनवरी 2006 D 4706 0 0 $0
James H Taylor JR Sr. VP, Operations 9 फ़रवरी 2005 M 9360 0 0 $0
Dennis A Ocwieja SVP, Regulatory 3 जनवरी 2005 A — 0 0 $0
Robert G Maclean SVP, HR 3 जनवरी 2005 A 36502 0 0 $0
Edward J Ludwig निदेशक 31 जुलाई 2026 P 30359 2 0 $430314
JOHNSON KRISTINA M निदेशक 3 मई 2016 A 8494 0 0 $0
Nicholas J Nicholas JR निदेशक 1 अप्रैल 2016 A 0 0 0 $0
NICHOLAS PETER M निदेशक 1 अप्रैल 2016 A 3486965 0 0 $0
Ernest Mario निदेशक 16 नवमबर 2015 S 86032 0 0 $0
Uwe E Reinhardt निदेशक 31 अक्टूबर 2014 A 159379 0 0 $0
Bruce L Byrnes निदेशक 31 अक्टूबर 2014 A 112097 0 0 $0
Katharine T Bartlett निदेशक 7 मई 2013 A 52464 0 0 $0
John Raymond Elliott निदेशक 27 फ़रवरी 2012 A 603676 0 0 $0
Ray J Groves निदेशक 31 मार्च 2011 A 1000 0 0 $0
Marye Anne Fox निदेशक 11 मई 2010 A 21111 0 0 $0
John E Pepper निदेशक 31 मार्च 2010 A 58807 0 0 $0
Ursula M Burns निदेशक 5 मई 2009 A 32001 0 0 $0
Warren B Rudman निदेशक 5 मई 2009 A — 0 0 $0
Nancy Ann Deparle निदेशक 6 मई 2008 A 13886 0 0 $0
Joel Lawrence Fleishman निदेशक 6 मई 2008 A 125691 0 0 $0
PROMERICA LP 10% मालिक 7 अगस्त 2007 J 54635185 0 0 $0
Emily Woodworth — 11 अगस्त 2026 I 2930 0 0 $0
Jonathan Monson — 10 अगस्त 2026 I 9908 0 0 $0
David C Habiger — 5 अगस्त 2026 P 17160 5 0 $407941

SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S

कार्यकर्ता और 5%+ मालिक 7 होल्डिंग्स

जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।

फाइलर दाखिल किया दांव स्थिति उद्देश्य फाइलिंग
Boston Scientific Corporation, Boston Scientific Scimed, Inc. 25 अप्रैल 2008 — प्रारंभिक फाइलिंग M&A / बिक्री SEC
GUIDANT CORPORATION ( 3 फ़रवरी 2006 — प्रारंभिक फाइलिंग — SEC
अघोषित रिपोर्टिंग व्यक्ति 14 फ़रवरी 2003 — प्रारंभिक फाइलिंग — SEC
अघोषित रिपोर्टिंग व्यक्ति 14 फ़रवरी 2003 — प्रारंभिक फाइलिंग — SEC
अघोषित रिपोर्टिंग व्यक्ति 27 जून 2002 — प्रारंभिक फाइलिंग — SEC
अघोषित रिपोर्टिंग व्यक्ति 23 मई 2002 — प्रारंभिक फाइलिंग M&A / बिक्री SEC
अघोषित रिपोर्टिंग व्यक्ति 9 जुलाई 2001 — प्रारंभिक फाइलिंग M&A / बिक्री SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ईटीएफ स्वामित्व 202 ETFs द्वारा धारित

वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।

फंड भार इकाइयाँ तिथि अनुसार स्रोत
IHI · iShares Trust 4.21% 2859807 SH 8 अगस्त 2026 दैनिक
GDOC · Goldman Sachs ETF Trust 3.78% 15740 NS 31 मई 2026 N-PORT
AGNG · Global X Funds 2.44% 41335 NS 31 मई 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2.04% 3946 NS 30 अप्रैल 2026 N-PORT
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1.68% 15586 NS 30 अप्रैल 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1.62% 60302 SH 8 अगस्त 2026 दैनिक
RSPH · Invesco Exchange-Traded Fund Trust 1.54% 245177 SH 8 अगस्त 2026 दैनिक
RUNN · Strategic Trust 1.54% 109930 NS 31 मई 2026 N-PORT
FMED · Fidelity Covington Trust 1.44% 12185 NS 31 मई 2026 N-PORT
HRTS · Tema ETF Trust 1.42% 15285 NS 31 मई 2026 N-PORT
SPGP · Invesco Exchange-Traded Fund Trust 1.38% 652401 SH 8 अगस्त 2026 दैनिक
FHLC · FIDELITY COVINGTON TRUST 1.38% 683394 NS 30 अप्रैल 2026 N-PORT
CURE · Direxion Shares ETF Trust 1.23% 29571 NS 30 अप्रैल 2026 N-PORT
IYH · iShares Trust 1.19% 887844 SH 8 अगस्त 2026 दैनिक
MEDI · Harbor ETF Trust 1.10% 5252 NS 30 अप्रैल 2026 N-PORT
RXL · ProShares Trust 1.04% 15464 NS 31 मई 2026 N-PORT
ESLG · Strategy Shares 0.97% 3256 NS 30 अप्रैल 2026 N-PORT
VHT · VANGUARD WORLD FUND 0.93% 4467628 SH 8 अगस्त 2026 दैनिक
IXJ · iShares Trust 0.92% 779800 SH 8 अगस्त 2026 दैनिक
ANEW · ProShares Trust 0.92% 1476 NS 31 मई 2026 N-PORT
GURU · Global X Funds 0.83% 8375 NS 30 अप्रैल 2026 N-PORT
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 0.79% 14552 NS 30 अप्रैल 2026 N-PORT
ESLV · Strategy Shares 0.66% 1338 NS 30 अप्रैल 2026 N-PORT
DTEC · ALPS ETF Trust 0.63% 9723 NS 31 मई 2026 N-PORT
ESUM · Strategy Shares 0.62% 16531 NS 30 अप्रैल 2026 N-PORT
NBGX · Neuberger Berman ETF Trust 0.60% 1844 NS 31 मई 2026 N-PORT
IIGD · Invesco Exchange-Traded Self-Indexe… 0.56% 160000 8 अगस्त 2026 दैनिक
FFLC · FIDELITY COVINGTON TRUST 0.54% 105660 NS 30 अप्रैल 2026 N-PORT
ZECP · Zacks Trust 0.52% 36519 NS 31 मई 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0.46% 91846 SH 8 अगस्त 2026 दैनिक
FFLG · FIDELITY COVINGTON TRUST 0.46% 46964 NS 30 अप्रैल 2026 N-PORT
CAPE · DoubleLine ETF Trust 0.44% 18128 NS 31 मार्च 2026 N-PORT
INFO · Harbor ETF Trust 0.43% 57055 NS 30 अप्रैल 2026 N-PORT
XOEF · iShares Trust 0.40% 1861 SH 8 अगस्त 2026 दैनिक
CATH · Global X Funds 0.40% 83468 NS 30 अप्रैल 2026 N-PORT
RCGE · EA Series Trust 0.39% 6410 NS 30 अप्रैल 2026 N-PORT
JGLO · J.P. Morgan Exchange-Traded Fund Tr… 0.39% 477916 NS 30 अप्रैल 2026 N-PORT
FWD · AB Active ETFs, Inc. 0.39% 230737 NS 31 मई 2026 N-PORT
SNPG · DBX ETF Trust 0.38% 1068 NS 29 मई 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 0.37% 56542 NS 30 अप्रैल 2026 N-PORT
KRMA · Global X Funds 0.36% 8982 NS 31 मई 2026 N-PORT
HELO · J.P. Morgan Exchange-Traded Fund Tr… 0.36% 250378 NS 30 अप्रैल 2026 N-PORT
CRTC · DBX ETF Trust 0.33% 8980 NS 31 मई 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0.30% 8609000 8 अगस्त 2026 दैनिक
OEI · Listed Funds Trust 0.29% 2132 NS 30 अप्रैल 2026 N-PORT
DFUV · Dimensional ETF Trust 0.29% 713544 NS 30 अप्रैल 2026 N-PORT
MGK · VANGUARD WORLD FUND 0.28% 2161888 SH 8 अगस्त 2026 दैनिक
HAPI · Harbor ETF Trust 0.28% 22510 NS 30 अप्रैल 2026 N-PORT
IWX · iShares Trust 0.27% 219287 SH 8 अगस्त 2026 दैनिक
IQSU · New York Life Investments ETF Trust 0.26% 14401 NS 30 अप्रैल 2026 N-PORT